|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Classic RAS blockers such as angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent AF by affecting the accumulation of the EAT, representing a useful therapeutic strategy for preventing AF especially in patients with heart failure and known left ventricular dysfunction.
|
31375968 |
2020 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Age, smoking history, diabetes mellitus,hypertension frequency, angiotensin converting enzyme inhibitor-angiotensin receptor blocker use, CHA₂DS₂VASc and HAS-BLED scores, serum sST2 level, left atrium (LA) end-diastolic diameter, LA volume and LA volume index were related to AF recurrence.
|
30238709 |
2018 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the effects of angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on thrombogenicity in AF remain incompletely elucidated.
|
28980280 |
2018 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additional treatment options in selected patients with persistent HF associated with reduced left ventricular ejection fraction include switching the angiotensin-converting enzyme inhibitor to an angiotensin receptor neprilysin inhibitor; ivabradine; implantable cardioverter defibrillators; cardiac resynchronisation therapy; and atrial fibrillation ablation.
|
30067937 |
2018 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Blockade of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARB) has been shown to decrease incident atrial fibrillation (AF).
|
30057228 |
2018 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study is to investigate whether treatment with ACE inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) could lower the risk of new AF in HCM.
|
29371376 |
2018 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Significant differences in the local conformations and kinetic properties of heart and lung ACEs demonstrate tissue specificity of ACE and provide a structural base for the development of mAbs able to distinguish heart and lung ACEs as a potential blood test for predicting atrial fibrillation risk.
|
28771512 |
2017 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and statins were of statistical significance for stroke risks.The majority of AF patients post-RFAs was of high stroke risk and received warfarin thromboprophylaxis in accordance with national guidelines.
|
29381974 |
2017 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
After optimal up-titration of BBs and angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), mean HR in patients with AF was 73 ± 15 beats/minute (bpm), 36% had resting HR ≤65 bpm.
|
28393567 |
2017 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin system (RAS) inhibition via angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce the risk of developing atrial fibrillation (AF) in certain populations, but the evidence is conflicting.
|
27179719 |
2016 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Individuals with the ACE D/D genotype appear to be at higher risk of AF.
|
26041129 |
2015 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to investigate the association of the angiotensin-converting enzyme 2350 G/A polymorphism with atrial fibrillation in Han Chinese patients with essential hypertension.
|
24270955 |
2013 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic ACE I/D polymorphism and recurrence of atrial fibrillation after catheter ablation.
|
23876437 |
2013 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We identified 21 SNPs and the angiotensin-converting enzyme insertion/deletion polymorphism that were reported to be associated with AF in the literature.
|
21056700 |
2011 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of the angiotensin-converting enzyme and angiotensinogen gene in patients with atrial fibrillation.
|
21436211 |
2011 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis suggests that there is insufficient evidence to demonstrate an association between ACE I/D polymorphism and AF risk.
|
21076147 |
2011 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results suggested an association between ACE insertion/deletion and AF risk.
|
20826259 |
2010 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association between polymorphism in angiotensinogen (AGT) and angiotensin-converting enzyme gene and risk of acquired AF in a pair-matched case-control study conducted in Chinese Hans.
|
19932491 |
2010 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
This article reviews clinical trials on the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) for the prevention of AF.
|
20636314 |
2010 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study suggests that ACE I/D polymorphism is associated with AF and the DD genotype may be an independent predictive factor for AF in patients with hypertensive heart disease.
|
19117407 |
2009 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Our study suggests that ACE I/D polymorphism is associated with AF and the DD genotype may be an independent predictive factor for AF in patients with hypertensive heart disease.
|
19117407 |
2009 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The T allele carriers (TT + CT) had significantly increased risk of AF compared with the CC homozygotes (OR 1.94, 95% CI 1.20-3.14; adjusted P=0.006) in a logistic regression model after controlling age, left atrial dimension, and the use of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers.
|
19665460 |
2009 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population.
|
18496132 |
2008 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen a-20c genotype alone and in combination with ACE I/D genotype predicts an increased risk of atrial fibrillation.
|
18496132 |
2008 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although activation of the renin-angiotensin-aldosterone system (RAAS) now appears to play a role in the pathophysiology of atrial fibrillation (AF), it remains to be determined if ACE genotype impacts response to conventional AAD therapy in patients with AF.
|
17556195 |
2007 |